| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.
|
Nat Med
|
2008
|
11.49
|
|
2
|
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
|
J Clin Invest
|
2011
|
6.38
|
|
3
|
Inducible apoptosis as a safety switch for adoptive cell therapy.
|
N Engl J Med
|
2011
|
6.14
|
|
4
|
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis.
|
Lancet Oncol
|
2010
|
4.67
|
|
5
|
Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.
|
JAMA
|
2011
|
4.52
|
|
6
|
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.
|
Nat Med
|
2006
|
4.42
|
|
7
|
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.
|
Blood
|
2004
|
4.01
|
|
8
|
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.
|
Blood
|
2007
|
3.94
|
|
9
|
Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.
|
JAMA
|
2012
|
3.91
|
|
10
|
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.
|
Blood
|
2011
|
3.82
|
|
11
|
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
|
J Clin Oncol
|
2013
|
3.65
|
|
12
|
Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.
|
JAMA
|
2012
|
3.30
|
|
13
|
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.
|
Blood
|
2009
|
3.27
|
|
14
|
Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival.
|
Biol Blood Marrow Transplant
|
2007
|
2.60
|
|
15
|
Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.
|
Blood
|
2009
|
2.47
|
|
16
|
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction.
|
Am Heart J
|
2009
|
2.29
|
|
17
|
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.
|
Blood
|
2013
|
2.13
|
|
18
|
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.
|
Blood
|
2013
|
1.95
|
|
19
|
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs).
|
Blood
|
2006
|
1.75
|
|
20
|
Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.
|
J Virol
|
2007
|
1.70
|
|
21
|
Prompt versus preemptive intervention for EBV lymphoproliferative disease.
|
Blood
|
2004
|
1.57
|
|
22
|
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.
|
Tex Heart Inst J
|
2010
|
1.52
|
|
23
|
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.
|
Blood
|
2008
|
1.52
|
|
24
|
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.
|
Blood
|
2010
|
1.44
|
|
25
|
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.
|
Blood
|
2002
|
1.40
|
|
26
|
Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients.
|
Am J Transplant
|
2005
|
1.36
|
|
27
|
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.
|
Cytotherapy
|
2012
|
1.27
|
|
28
|
Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale.
|
Am Heart J
|
2011
|
1.13
|
|
29
|
Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.
|
J Immunol
|
2002
|
1.06
|
|
30
|
Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.
|
Cytotherapy
|
2011
|
1.00
|
|
31
|
Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.
|
Cytotherapy
|
2012
|
0.98
|
|
32
|
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.
|
Blood
|
2005
|
0.96
|
|
33
|
Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience.
|
Cytotherapy
|
2010
|
0.94
|
|
34
|
Manufacturing mesenchymal stromal cells for phase I clinical trials.
|
Cytotherapy
|
2013
|
0.93
|
|
35
|
The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes.
|
Biol Blood Marrow Transplant
|
2009
|
0.92
|
|
36
|
Cell therapies for traumatic brain injury.
|
Neurosurg Focus
|
2008
|
0.89
|
|
37
|
Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection.
|
Clin Transplant
|
2006
|
0.89
|
|
38
|
Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies.
|
Transfusion
|
2008
|
0.88
|
|
39
|
Donor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2011
|
0.87
|
|
40
|
Rapid transport and infusion of hematopoietic cells is associated with improved outcome after myeloablative therapy and unrelated donor transplant.
|
Biol Blood Marrow Transplant
|
2009
|
0.87
|
|
41
|
Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
|
Clin Transplant
|
2006
|
0.86
|
|
42
|
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.
|
J Clin Invest
|
2016
|
0.85
|
|
43
|
CD34(+) cell selection using small-volume marrow aspirates: a platform for novel cell therapies and regenerative medicine.
|
Cytotherapy
|
2010
|
0.82
|
|
44
|
Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study.
|
Transfusion
|
2012
|
0.80
|
|
45
|
An update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: a decade of cell therapy.
|
Clin Transl Sci
|
2014
|
0.80
|
|
46
|
Cell therapy product administration and safety: data capture and analysis from the Production Assistance for Cellular Therapies (PACT) program.
|
Transfusion
|
2014
|
0.77
|
|
47
|
How to design a cell or gene therapy clinical trial: advice from the FDA.
|
Mol Ther
|
2013
|
0.75
|
|
48
|
[Impact of regulations on translational research in cell and gene therapy: the American experience].
|
Bull Cancer
|
2004
|
0.75
|